SCM
ACRS icon

Superstring Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Superstring Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Sell
257,675
-108,815
-30% -$485K 0.86% 23
2026
Q1 		$1.37M Buy
+366,490
New +$1.24M 0.98% 26

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Superstring Capital Management's ACRS Position: Q2 2026 in Review

Superstring Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 30% in Q2 2026, selling an estimated $485K and leaving 257,675 shares worth $1.36M. The position accounts for 0.86% of the portfolio, ranked #23.

Superstring Capital Management first reported a position in ACRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.37M in Q1 2026. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Superstring Capital Management held 257,675 shares of Aclaris Therapeutics worth $1.36M as of Q2 2026.
  • Superstring Capital Management sold 108,815 Aclaris Therapeutics shares in Q2 2026, an estimated $485K.
  • Aclaris Therapeutics made up 0.86% of Superstring Capital Management's portfolio in Q2 2026, its #23 holding.
  • Superstring Capital Management first reported a position in Aclaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Superstring Capital Management's Aclaris Therapeutics position peaked at $1.37M in Q1 2026.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.